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Introduction
Apgar et al. (2007) defined Menorrhagia as menstrual blood
loss of C80 mL per cycle [1]. The current recommendation
is to replace the term ‘menorrhagia’ by ‘heavy menstrual
bleeding’ (HMB), as the former term is confusing with Latin and
Greek roots which are loosely defined in the English medical
language. In addition, the 80-mL criterion is of limited clinical
prognostic value. HMB is a universal health problem affecting
up to 30% of women in reproductive age and negatively
impacting their physical activities and health-related quality
of life. The National Institute for Clinical Excellence in the UK
defines HMB as ‘‘excessive menstrual blood loss that interferes
with the woman’s physical, emotional, social, and/or material
quality of life’’. Idiopathic HMB is regular heavy bleeding in the
absence of recognizable pelvic pathology or a general bleeding
disorder. Fibroids have been found in up to 40% of women
with HMB; however, half of all women having a hysterectomy
for HMB are found to have a normal uterus . There are data
suggesting that unrestrained local inflammatory events and/
or deficient repair processes within the endometrium may
contribute to the onset of HMB Accordingly, medical therapy,
e.g., non-steroidal anti-inflammatory drugs, antifibrinolytics,
oral contraceptive pills, progestogens and other hormones,
and levonorgestrel-releasing intrauterine system represents
an attractive option to avoid unnecessary surgery (e.g., uterine
ablation and hysterectomy).
Stemler (2004) states that menorrhagia is a common condition.
Approximately 5% of females seek medical attention for it [2].
Menorrhagia is defined as cyclic menstrual bleeding producing
more than 80 mL of blood and/or bleeding for more than seven
consecutive days. Most individuals cannot accurately quantify
the amount of menstrual bleeding in milliliters. Therefore, it is
often helpful to ask the patient how the menses is disrupting her
lifestyle. Most women have a consistent pattern of menstrual
bleeding from month to month. When an excessive amount of

bleeding is present during the expected menstrual cycle, an
underlying organic or hematologic etiology must be considered.
Since the definition of heavy menstrual bleeding varies, it is
important to have guidelines for it. A normal menstrual pattern
occurs every 21 to 35 days and lasts from two to seven days.
Women lose approximately 30 to 40 cc of blood each cycle,
which represents eight soaked pads or tampons per menses.
Byams (2007) defines menorrhagia or excessive menstrual
bleeding as a common clinical problem that affects 8–10%
of women of reproductive age [3]. Because menorrhagia has
many physical causes, including uterine fibroids, endometriosis,
thyroid problems, and cancer, physicians traditionally focus
on the organic pathology of the uterus. However, one study
showed that a cause for menorrhagia is never identified in
approximately 50% of cases.3 The results of recent studies
indicate that between 5% and 24% of women with menorrhagia
may have undiagnosed von Willebrand disease (VWD), and as
many as 2 million women in the United States may have either
VWD or another type of bleeding disorder without knowing
it. VWD is the most common bleeding disorder, affecting just
over 1% of the general population. It is caused by a deficiency
in the body’s ability to make a protein, von Willebrand factor,
which localizes platelets to the site of bleeding and helps blood
clot. Although VWD occurs with equal frequency among men
and women, women are more likely to experience symptoms
of VWD because of the increased bleeding it causes during
their menstrual periods, during pregnancy, and after childbirth.
Women with menorrhagia or VWD or both are at an increased
risk for pain during menstruation, anemia, hospitalizations,
blood transfusions, limitations in daily activities, time lost
from work or school, adverse psychosocial effects, and a
reduced quality of life (QOL). The results of a recent study
showed that women with VWD reported poorer health-related
QOL than women in the general population.6 Women with
menorrhagia often undergo unnecessary surgical interventions
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to relieve heavy menstrual bleeding. At least 60% of women
with uncontrolled menorrhagia undergo hysterectomies or
other surgical procedures, including endometrial ablation and
dilation and curettage. With proper diagnoses, many women
with bleeding disorders could avoid these complications and
surgeries, decrease their level of menstrual bleeding, and
improve their QOL. The Division of Blood Disorders (DBD) at the
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Centers for Disease Control and Prevention (CDC) has worked to
assess physicians’ awareness of bleeding disorders, determine
the prevalence of bleeding disorders among women, and
evaluate the options for treating women with these disorders.
Descriptions of some of the DBD’s activities within their Women
with Bleeding Disorders program follow (Table 1)

Differential Diagnosis
anticoagulants, nonsteroidal antiinflammatory

Infection: chlamydia/gonorrhea/Incomplete abortion

contraceptive, acetylsalicylic acid,

Trauma/sexual abuse

sepsis, leukemia, aplastic anemia,

Trichomonas

thrombocytopenia, idiopathic

Pregnancy/ectopic pregnancy/

Willebrand disease, liver disease,

Trophoblastic disease/spontaneous

polycystic ovarian syndrome

Trauma/sexual abuse

Foreign body
Medication induced:
Treatment
For AZ, desmopressin acetate (DDAVP) nasal spray (Stimate) was
chosen to help control her menorrhagia. Desmopressin acetate
is the treatment of choice for vWD Type 1.13,36 Desmopressin
may be given intravenously or intranasally, but the intranasal
spray is equally efficacious and more convenient.36 Patients
should also use desmopressin acetate prophylactically before
minor outpatient gynecological surgeries, as well as for other
mucosal or dental procedures. Desmopressin acetate promotes
the release of normal functioning vWF from the blood vessel’s
endothelial cell lining. It strengthens hemostasis by decreasing
the bleeding time and increasing the levels of factor VIII and
the (Abu, 2013) [4] .
Frazer et al., 2011, stated that both surgical and medical
interventions are available for the treatment of heavy menstrual
bleeding [5]. Treatments include the levonorgestrel-releasing
intrauterine system (LNG-IUS), tranexamic acid, non-steroidal
anti-inflammatory drugs, danazol, cyclical progestogens, and
combined oral contraceptives (COCs). With the exception
of the LNG-IUS, cyclical progestogens, and tranexamic acid,
most medical treatments are prescribed off-label and without
perspective, well-designed studies that validate or quantify
their effect. Although COCs are used widely off-label for the
treatment of heavy or prolonged menstrual bleeding, prior
to 2009, no large-scale objective, randomised or placebocontrolled data existed in the literature to support their
use for this purpose 6, with only one small randomised trial
reported. Surgical procedures, such as hysterectomy and

endometrial ablation, offer effective strategies, but their cost
and associated morbidity should limit these approaches to
patients with whom medical therapies have failed. A novel
and effective oral contraceptive containing estradiol valerate
and dienogest (E 2V/DNG) have been shown to be associated
with good cycle control and a good tolerability profile. This
oral contraceptive has been available since May 2009 in many
countries worldwide under the trade names Qlaira ® or Natazia
TM. Recently, two identically designed Phase III trials, one
conducted in Europe and Australia and the other in North
America, were undertaken to evaluate the efficacy and safety
of E 2V/DNG in the treatment of heavy and/or prolonged
menstrual bleeding. This paper details the reduction in MBL and
safety findings as well as the patients’ and investigators’ rating
of the improvement in bleeding symptoms from an analysis of
pooled data from these two Phase III clinical trials. By pooling
data from the available studies, we sought to better define
the decrease in MBL achieved with E 2V/DNG and its safety
profile across a larger and more diverse population of women.
A pooled analysis of these trials was judged to be appropriate
because of their identical design and enrollment criteria.
Patient Education
After AZ’s condition was diagnosed, her NP made sure she was
thoroughly educated about vWD. She was instructed to report
any breakthrough bleeding or irregular menses. Women with
vWD have heavier menses. If menstrual bleeding occurs at other
times, then another source must be ruled out. AZ was instructed
to report headaches, muscle weakness, nausea, vomiting,
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and seizures because these can be signs of hyponatremia.
The patient must avoid aspirin as well as nonsteroidal antiinflammatory drugs due to the risk of further defects in platelet
function. AZ was instructed to inform all providers of her new
diagnosis of vWD, especially before surgical procedures to the
mucous membranes (mouth, nose, and throat). The patient
should be taught the important factors to consider, which
include her age, whether her family is complete, contraceptive
requirements, the severity of her symptoms, and the patient’s
culture and beliefs. Troublesome periods are a common
problem, and nurses are likely to encounter women with them
during the course of their practice, irrespective of whether
they work in women’s health or gynecology. It is important to
encourage women to describe their symptoms by establishing
an open, accepting relationship, taking time, and asking the
correct questions. It is also important for nurses to have a clear
understanding of the normal menstrual function and blood
clotting so that they can identify possible abnormalities that
merit further investigation. Today much more can be done to
relieve the symptoms of menorrhagia. Women do not need to
endure heavy, painful bleeding, and they may need sympathetic
support to encourage them to access what is available and
select the best treatment to suit their particular circumstances
(Gould, 2007) [6].
Implications for practice
These findings suggest that more effort may have to be made by
the GP to understand the woman’s concerns and expectations
regarding her menstrual symptoms and to explain the nature of
bodily functions and likely causes of these symptoms. Women
must be able to feel first that they have been listened to and
then diagnosed so that treatment options can then be properly
discussed, and a shared management decision reached.
Menorrhagia may be seen to represent an exemplary of other
problems that also cannot be objectively diagnosed, such as
irritable bowel syndrome and chronic lower back pain that is
presented in primary care and which GPs may be insufficiently
skilled in managing. The place for a decision aid to assist both
the GP and the woman with menorrhagia needs careful but
urgent evaluation.
Directions of Future Research
Although researchers have made much progress in establishing
the prevalence of bleeding disorders among women and
evaluating the management options available to them and their
physicians, DBD remains committed to expanding research
in the area of women with bleeding disorders. DBD and its
partners are currently developing a surveillance instrument
to assess the prevalence of various problems among women
and girls with diagnosed bleeding disorders who are receiving
care at a network of federally funded hemophilia treatment
centers (HTCs). HTCs were originally created to treat males
with hemophilia; however, the number of females with
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bleeding problems seeking care at these centers has increased
steadily over the last 10 years from 4800 to almost 9000. The
main purpose of this data collection is to better characterize
reproductive and other symptoms among women with blood
disorders over time. DBD will also collect data on diagnoses,
treatments, HTC referral patterns, and study participants’
QOL. Although menorrhagia is highly prevalent among women
with bleeding disorders, it is not the only gynecological
manifestation of these conditions: bleeding disorders have
also been associated with an increased risk for ovarian
cysts, endometriosis, fibroids, miscarriage, bleeding during
pregnancy, and postpartum hemorrhage. However, because
few prospective, casecontrol studies have compared the
prevalence of these conditions among women with bleeding
disorders with the prevalence among controls, a causal
relationship has not been established. DBD plans to expand its
research in order to elucidate the association between bleeding
disorders and women’s risks for various adverse obstetrical
and gynecological outcomes. The ultimate goals of the DBD
Women with Bleeding Disorders program are to improve
women’s QOL through the recognition, proper diagnosis,
and management of bleeding disorders, reduce unnecessary
surgical procedures among women with these disorders, and
contribute to the development of a national protocol for the
diagnosis, treatment, and management of bleeding disorders
among women. Through the current and future activities
described here, the program is making substantial progress
toward meeting these goals as well as in supporting its mission
to prevent and reduce morbidity associated with bleeding
disorders among women (Hurskainen et al., 2004) [7-10].
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